Maze Therapeutics, Inc.
MAZE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001842295
In the last 90 days, Maze Therapeutics, Inc. insiders filed 0 open-market purchases and 14 sales; 161 institutions reported holding it in 13F filings for Q2 2026, worth $1.75B in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Holders of 5% or more of MAZE
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Maze Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| ARCH Venture Fund X, L.P. | 13G | 9.40%4.12M shares | New | May 15, 20251 filing | May 15, 2025 | SEC |
| Third Rock Ventures IV, L.P. | 13G/A | 9.30%4.47M shares | −4.60 ppfrom 13.90% | May 9, 20252 filings | Feb 13, 2026 | SEC |
| Deep Track Capital, LP | 13G/A | 9.02%3.95M shares | +2.11 ppfrom 6.91% | Feb 7, 20252 filings | Aug 14, 2025 | SEC |
| Frazier Life Sciences Public Fund, L.P. | 13G/A | 9.00%4.34M shares | +1.30 ppfrom 7.70% | Feb 10, 20255 filings | Feb 13, 2026 | SEC |
| Janus Henderson Group PLC | 13G/A | 5.80%2.86M shares | −1.50 ppfrom 7.30% | May 14, 20254 filings | May 15, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.40%2.98M shares | New | Jul 29, 20261 filing | Jul 29, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
24 Schedule 13D and 13G filings on Maze Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20264:21 PM ET | Paradigm Biocapital Advisors LPand 3 others | 13G/A | 0.00%0 shares | −6.10 ppfrom 6.10%Below 5% | Jun 30, 2026 | SEC |
| Jul 29, 20263:19 PM ET | BlackRock, Inc. | 13G | 5.40%2.98M shares | New | Jun 30, 2026 | SEC |
| May 15, 202612:37 PM ET | Janus Henderson Group PLC | 13G/A | 5.80%2.86M shares | −1.50 ppfrom 7.30% | Mar 31, 2026 | SEC |
| Apr 1, 20264:00 PM ET | Paradigm Biocapital Advisors LPand 3 others | 13G | 6.10%3.05M shares | New | Mar 25, 2026 | SEC |
| Feb 13, 20265:31 PM ET | Frazier Life Sciences Public Fund, L.P.and 13 others | 13G/A | 9.00%4.34M shares | +1.30 ppfrom 7.70% | Dec 31, 2025 | SEC |
| Feb 13, 20265:25 PM ET | Third Rock Ventures IV, L.P.and 5 others | 13G/A | 9.30%4.47M shares | −4.60 ppfrom 13.90% | Dec 31, 2025 | SEC |
| Feb 6, 20264:32 PM ET | GV 2019, L.P.and 8 others | 13G/A | 2.90%1.39M shares | −2.60 ppfrom 5.50%Below 5% | Dec 31, 2025 | SEC |
| Nov 14, 20254:04 PM ET | Foresite Capital Fund IV, L.P.and 4 others | 13G/A | 1.40%608.9K shares | −4.20 ppfrom 5.60%Below 5% | Sep 30, 2025 | SEC |
| Nov 14, 202512:49 PM ET | Janus Henderson Group PLC | 13G/A | 7.30%3.21M shares | +1.30 ppfrom 6.00% | Sep 30, 2025 | SEC |
| Nov 13, 20254:10 PM ET | Matrix Capital Management Company, LPand 1 other | 13G/A | 3.50%1.65M shares | −2.20 ppfrom 5.70%Below 5% | Sep 30, 2025 | SEC |
| Aug 14, 20251:43 PM ET | Frazier Life Sciences Public Fund, L.P.and 16 others | 13G/A | 7.70%3.35M shares | −2.50 ppfrom 10.20% | Jun 30, 2025 | SEC |
| Aug 14, 202511:46 AM ET | Janus Henderson Group PLC | 13G/A | 6.00%2.63M shares | +0.30 ppfrom 5.70% | Mar 31, 2025 | SEC |
| Aug 14, 20258:48 AM ET | Deep Track Capital, LPand 2 others | 13G/A | 9.02%3.95M shares | +2.11 ppfrom 6.91% | Jun 30, 2025 | SEC |
| May 15, 20255:05 PM ET | ARCH Venture Fund X, L.P.and 8 others | 13G | 9.40%4.12M shares | New | Mar 31, 2025 | SEC |
| May 14, 20254:10 PM ET | Matrix Capital Management Company, LPand 1 other | 13G | 5.70%2.49M shares | New | Mar 31, 2025 | SEC |
| May 14, 202511:48 AM ET | Janus Henderson Group PLC | 13G | 5.70%2.50M shares | New | Mar 31, 2025 | SEC |
| May 9, 20254:15 PM ET | GV 2019, L.P.and 8 others | 13G | 5.50%2.41M shares | New | Mar 31, 2025 | SEC |
| May 9, 20254:15 PM ET | Third Rock Ventures IV, L.P.and 5 others | 13G | 13.90%6.07M shares | New | Jan 31, 2025 | SEC |
| Apr 29, 20259:59 AM ET | Frazier Life Sciences Public Fund, L.P.and 16 others | 13G/A | 10.20%4.45M shares | +0.80 ppfrom 9.40% | Apr 25, 2025 | SEC |
| Apr 29, 20259:58 AM ET | Frazier Life Sciences Public Fund, L.P.and 16 others | 13G/A | 9.40%4.13M shares | +2.10 ppfrom 7.30% | Mar 31, 2025 | SEC |
| Feb 10, 202510:55 AM ET | Frazier Life Sciences Public Fund, L.P.and 16 others | 13G | 7.30%3.19M shares | New | Feb 3, 2025 | SEC |
| Feb 7, 20254:30 PM ET | Deep Track Capital, LPand 2 others | 13G | 6.91%3.02M shares | New | Jan 31, 2025 | SEC |
| Feb 7, 20254:01 PM ET | Foresite Capital Fund IV, L.P.and 4 others | 13G | 5.60%2.46M shares | 0.00 ppfrom 5.60% | Jan 31, 2025 | SEC |
| Feb 7, 20254:01 PM ET | Foresite Capital Fund IV, L.P.and 4 others | 13G | 5.60%2.46M shares | New | Jan 31, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Maze Therapeutics, Inc. shares.
No Form 144 notices for Maze Therapeutics, Inc. are on file.